Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-2329 tablets, an innovative anti-tumor drug targeting late-stage solid tumors with RAS mutations or amplifications [1] Drug Information - Drug Name: HRS-2329 Tablets [1] - Dosage Form: Tablets [1] - Application Matter: Clinical Trial [1] - Acceptance Numbers: CXHL2500682, CXHL2500683, CXHL2500684 [1] - Approval Conclusion: The clinical trial application for HRS-2329 tablets, accepted on July 10, 2025, meets the requirements for drug registration and is approved for trials in patients with late-stage solid tumors carrying RAS mutations or amplifications [1] Development Status - HRS-2329 tablets are independently developed by the company and have shown good anti-tumor activity in preclinical animal models [1] - The drug is intended for the treatment of late-stage solid tumors with RAS mutations or amplifications [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] - The cumulative R&D investment for the HRS-2329 project is approximately 60.15 million yuan [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-2329 tablets, an innovative anti-tumor drug developed by the company, which shows promising anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors with RAS mutations or amplifications [1] Group 1 - HRS-2329 tablets are a self-developed innovative anti-tumor drug by the company [1] - The drug has demonstrated good anti-tumor activity in preclinical animal models [1] - There are currently no similar drugs approved for marketing domestically or internationally [1] Group 2 - The company has invested approximately 60.15 million yuan in the research and development of the HRS-2329 project to date [1]

Core Insights - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of HRS-2329 tablets, an innovative anti-tumor drug developed by the company [1] - HRS-2329 tablets have shown promising anti-tumor activity in preclinical animal models and are intended for the treatment of advanced solid tumors with RAS mutations or amplifications [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] - The total research and development investment for the HRS-2329 project has reached approximately 60.15 million yuan [1]

格隆汇9月30日丨恒瑞医药(600276.SH)公布，公司收到国家药品监督管理局核准签发关于HRS-2329片的 《药物临床试验批准通知书》，将于近期开展临床试验。HRS-2329片是公司自主研发的创新型抗肿瘤 药物，在临床前动物模型中展现出良好的抗肿瘤活性，拟用于治疗携带RAS突变或扩增的晚期实体瘤。 ...